PATENT CLAIM ANALYSIS

Application Number: 16074744
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "04400A"]

Abstract:
The present embodiments provide methods, compounds, and compositions useful for inhibiting KLK3 eRNA expression, which may be useful for treating, preventing, or ameliorating cancer, such as prostate cancer.

Claim (Index 3):
A composition comprising the compound of  claim 1  or  2  and a pharmaceutically acceptable carrier.

Metadata:
- Claim Count in Document: 15.0
- Percentile: 96.0
- Lexical Diversity: 1.2963
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14050574', '14854281', '14403103', '13436558', '15356947']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7075323388071989
- 35 USC 102 Novelty (BERT): 0.50627503569039
- Combined Prediction Score: 0.687406608495518
- Mean Citation Score: 234.977594
- Max Citation Score: 266.149
- Similarity Product: 210.14633655667305

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test